Pathogenic mechanisms of deregulated microRNA expression in thyroid carcinomas of follicular origin

Thyroid Research

Volumn 4, Issue SUPPL. 1, 2011, Pages

  Braun, Juliane ^a   Hüttelmaier, Stefan ^a  

^a MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 79961197418     PISSN: None     EISSN: 17566614     Source Type: Journal    
DOI: 10.1186/1756-6614-4-S1-S1     Document Type: Review

References (109)

1. Global cancer statistics. A Jemal F Bray MM Center J Ferlay E Ward D Forman, CA Cancer J Clin 61 2 69 90 21296855
2. Pathogenetic mechanisms in thyroid follicular-cell neoplasia. T Kondo S Ezzat SL Asa, Nat Rev Cancer 2006 6 292 306 10.1038/nrc1836 16557281
3. Molecular pathology of thyroid tumors. KW Schmid, Pathologe 2010 31 Suppl 2 229 233 20717681
4. Guest Editorial: Two Proposals Regarding the Terminology of Thyroid Tumors. ED Williams, Int J Surg Pathol 2000 8 181 183 10.1177/106689690000800304 11493987
5. World Health Organization Classification of Tumours, Pathology and Genetics of Tumours of Endocrine Organs. RA DeLellis RV L PU Heitz C Eng, 2004 49 133
6. Anaplastic thyroid carcinoma: a therapeutic challenge. KB Ain, Semin Surg Oncol 1999 16 64 69 10.1002/(SICI)1098-2388(199901/02)16:1<64::AID- SSU10>3.0.CO;2-U 9890741
7. Insular carcinoma: a distinct de novo entity among follicular carcinomas of the thyroid gland. S Pilotti P Collini L Mariani M Placucci I Bongarzone P Vigneri S Cipriani F Falcetta R Miceli MA Pierotti F Rilke, Am J Surg Pathol 1997 21 1466 1473 10.1097/00000478-199712000-00009 9414190 (Pubitemid 27528257)
8. Cancer after nuclear fallout: lessons from the Chernobyl accident. D Williams, Nat Rev Cancer 2002 2 543 549 10.1038/nrc845 12094241 (Pubitemid 37328936)
9. Thyroid cancer and thyroiditis in Salta, Argentina: a 40-yr study in relation to iodine prophylaxis. HR Harach DA Escalante ES Day, Endocr Pathol 2002 13 175 181 10.1385/EP:13:3:175 12446916 (Pubitemid 36021029)
10. Common variants on 9q22.33 and 14q13.3 predispose to thyroid cancer in European populations. J Gudmundsson P Sulem DF Gudbjartsson JG Jonasson A Sigurdsson JT Bergthorsson H He T Blondal F Geller M Jakobsdottir,, et al. Nat Genet 2009 41 460 464 10.1038/ng.339 19198613
11. Molecular diagnostics and predictors in thyroid cancer. MN Nikiforova YE Nikiforov, Thyroid 2009 19 1351 1361 10.1089/thy.2009.0240 19895341
12. Deregulation of microRNA expression in follicular-cell-derived human thyroid carcinomas. P Pallante R Visone CM Croce A Fusco, Endocr Relat Cancer 2010 17 91 104 10.1677/ERC-09-0217 19942715
13. Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. PT Wan MJ Garnett SM Roe S Lee D Niculescu-Duvaz VM Good CM Jones CJ Marshall CJ Springer D Barford R Marais, Cell 2004 116 855 867 10.1016/S0092-8674(04)00215-6 15035987 (Pubitemid 38410730)
14. Targeted expression of BRAFV600E in thyroid cells of transgenic mice results in papillary thyroid cancers that undergo dedifferentiation. JA Knauf X Ma EP Smith L Zhang N Mitsutake XH Liao S Refetoff YE Nikiforov JA Fagin, Cancer Res 2005 65 4238 4245 10.1158/0008-5472.CAN-05-0047 15899815 (Pubitemid 40775662)
15. Beta-catenin dysregulation in thyroid neoplasms: down-regulation, aberrant nuclear expression, and CTNNB1 exon 3 mutations are markers for aggressive tumor phenotypes and poor prognosis. G Garcia-Rostan RL Camp A Herrero ML Carcangiu DL Rimm G Tallini, Am J Pathol 2001 158 987 996 10.1016/S0002-9440(10)64045-X 11238046 (Pubitemid 32221790)
16. Absence of mutations in the beta-catenin and adenomatous polyposis coli genes in papillary and follicular thyroid carcinomas. N Miyake H Maeta S Horie Y Kitamura E Nanba K Kobayashi T Terada, Pathol Int 2001 51 680 685 10.1046/j.1440-1827.2001.01269.x 11696170 (Pubitemid 32989613)
17. Dysregulation of the phosphatidylinositol 3-kinase pathway in thyroid neoplasia. JE Paes MD Ringel, Endocrinol Metab Clin North Am 2008 37 375 387 viii-ix 10.1016/j.ecl.2008.01.001 18502332 (Pubitemid 351698084)
18. Small silencing RNAs: an expanding universe. M Ghildiyal PD Zamore, Nat Rev Genet 2009 10 94 108 10.1038/nrg2504 19148191
19. Regulation of mRNA translation and stability by microRNAs. MR Fabian N Sonenberg W Filipowicz, Annu Rev Biochem 2010 79 351 379 10.1146/annurev- biochem-060308-103103 20533884
20. New tricks for animal microRNAS: targeting of amino acid coding regions at conserved and nonconserved sites. I Rigoutsos, Cancer Res 2009 69 3245 3248 10.1158/0008-5472.CAN-09-0352 19351814
21. A limited set of human MicroRNA is deregulated in follicular thyroid carcinoma. F Weber RE Teresi CE Broelsch A Frilling C Eng, J Clin Endocrinol Metab 2006 91 3584 3591 10.1210/jc.2006-0693 16822819 (Pubitemid 44402141)
22. Activin A and activin receptors in thyroid cancer. KM Schulte C Jonas R Krebs HD Roher, Thyroid 2001 11 3 14 10.1089/10507250150500603 11272093 (Pubitemid 32127406)
23. Tetraspanins and malignancy. C Boucheix GH Duc C Jasmin E Rubinstein, Expert Rev Mol Med 2001 2001 1 17 14987376
24. Human fibulin-4: analysis of its biosynthetic processing and mRNA expression in normal and tumour tissues. WM Gallagher LM Greene MP Ryan V Sierra A Berger P Laurent-Puig E Conseiller, FEBS Lett 2001 489 59 66 10.1016/S0014-5793(00)02389-9 11231014 (Pubitemid 32176006)
25. Downregulation of several fibulin genes in prostate cancer. A Wlazlinski R Engers MJ Hoffmann C Hader V Jung M Muller WA Schulz, Prostate 2007 67 1770 1780 10.1002/pros.20667 17929269 (Pubitemid 350228729)
26. MicroRNA expression profiling of thyroid tumors: biological significance and diagnostic utility. MN Nikiforova GC Tseng D Steward D Diorio YE Nikiforov, J Clin Endocrinol Metab 2008 93 1600 1608 10.1210/jc.2007-2696 18270258 (Pubitemid 351656494)
27. MicroRNA deregulation in human thyroid papillary carcinomas. P Pallante R Visone M Ferracin A Ferraro MT Berlingieri G Troncone G Chiappetta CG Liu M Santoro M Negrini,, et al. Endocr Relat Cancer 2006 13 497 508 10.1677/erc.1.01209 16728577 (Pubitemid 43886672)
28. Specific microRNAs are downregulated in human thyroid anaplastic carcinomas. R Visone P Pallante A Vecchione R Cirombella M Ferracin A Ferraro S Volinia S Coluzzi V Leone E Borbone,, et al. Oncogene 2007 26 7590 7595 10.1038/sj.onc.1210564 17563749 (Pubitemid 350207711)
29. MicroRNAs (miR)-221 and miR-222, both overexpressed in human thyroid papillary carcinomas, regulate p27Kip1 protein levels and cell cycle. R Visone L Russo P Pallante I De Martino A Ferraro V Leone E Borbone F Petrocca H Alder CM Croce A Fusco, Endocr Relat Cancer 2007 14 791 798 10.1677/ERC-07-0129 17914108 (Pubitemid 350074067)
30. Downregulation of microRNAs directs the EMT and invasive potential of anaplastic thyroid carcinomas. J Braun C Hoang-Vu H Dralle S Huttelmaier, Oncogene 2010 29 4237 4244 10.1038/onc.2010.169 20498632
31. The role of microRNA genes in papillary thyroid carcinoma. H He K Jazdzewski W Li S Liyanarachchi R Nagy S Volinia GA Calin CG Liu K Franssila S Suster,, et al. Proc Natl Acad Sci U S A 2005 102 19075 19080 10.1073/pnas.0509603102 16365291 (Pubitemid 43049568)
32. MicroRNA expression, survival, and response to interferon in liver cancer. J Ji J Shi A Budhu Z Yu M Forgues S Roessler S Ambs Y Chen PS Meltzer CM Croce,, et al. N Engl J Med 2009 361 1437 1447 10.1056/NEJMoa0901282 19812400
33. Therapeutic microRNA delivery suppresses tumorigenesis in a murine liver cancer model. J Kota RR Chivukula KA O'Donnell EA Wentzel CL Montgomery HW Hwang TC Chang P Vivekanandan M Torbenson KR Clark,, et al. Cell 2009 137 1005 1017 10.1016/j.cell.2009.04.021 19524505
34. Identification of let-7-regulated oncofetal genes. B Boyerinas SM Park N Shomron MM Hedegaard J Vinther JS Andersen C Feig J Xu CB Burge ME Peter, Cancer Res 2008 68 2587 2591 10.1158/0008-5472.CAN-08-0264 18413726 (Pubitemid 351556256)
35. Effects of let-7 microRNA on Cell Growth and Differentiation of Papillary Thyroid Cancer. JC Ricarte-Filho CS Fuziwara AS Yamashita E Rezende MJ da-Silva ET Kimura, Transl Oncol 2009 2 236 241 19956384
36. Analysis of deregulated miRNAs is helpful to distinguish poorly differentiated thyroid carcinoma from papillary thyroid carcinoma. S Schwertheim SY Sheu K Worm F Grabellus KW Schmid, Horm Metab Res 2009 41 475 481 10.1055/s-0029-1215593 19370508
37. Differential miRNA expression profiles in variants of papillary thyroid carcinoma and encapsulated follicular thyroid tumours. SY Sheu F Grabellus S Schwertheim K Worm M Broecker-Preuss KW Schmid, Br J Cancer 2010 102 376 382 10.1038/sj.bjc.6605493 20029416
38. Differential expression of miRNAs in papillary thyroid carcinoma compared to multinodular goiter using formalin fixed paraffin embedded tissues. MT Tetzlaff A Liu X Xu SR Master DA Baldwin JW Tobias VA Livolsi ZW Baloch, Endocr Pathol 2007 18 163 173 10.1007/s12022-007-0023-7 18058265 (Pubitemid 351384379)
39. MicroRNA analysis as a potential diagnostic tool for papillary thyroid carcinoma. YT Chen N Kitabayashi XK Zhou TJ Fahey 3rd T Scognamiglio, Mod Pathol 2008 21 1139 1146 10.1038/modpathol.2008.105 18587330
40. Effect of BRAFV600E mutation on transcription and post-transcriptional regulation in a papillary thyroid carcinoma model. S Cahill P Smyth K Denning R Flavin J Li A Potratz SM Guenther R Henfrey JJ O'Leary O Sheils, Mol Cancer 2007 6 21 10.1186/1476-4598-6-21 17355635
41. Effect of ret/PTC 1 rearrangement on transcription and post-transcriptional regulation in a papillary thyroid carcinoma model. S Cahill P Smyth SP Finn K Denning R Flavin EM O'Regan J Li A Potratz SM Guenther R Henfrey,, et al. Mol Cancer 2006 5 70 10.1186/1476-4598-5-70 17156473
42. Oncogenic role of miR-17-92 cluster in anaplastic thyroid cancer cells. S Takakura N Mitsutake M Nakashima H Namba VA Saenko TI Rogounovitch Y Nakazawa T Hayashi A Ohtsuru S Yamashita, Cancer Sci 2008 99 1147 1154 10.1111/j.1349-7006.2008.00800.x 18429962 (Pubitemid 351676626)
43. Downregulation of miR-138 is associated with overexpression of human telomerase reverse transcriptase protein in human anaplastic thyroid carcinoma cell lines. S Mitomo C Maesawa S Ogasawara T Iwaya M Shibazaki A Yashima-Abo K Kotani H Oikawa E Sakurai N Izutsu,, et al. Cancer Sci 2008 99 280 286 10.1111/j.1349-7006.2007.00666.x 18201269 (Pubitemid 351228481)
44. Upregulation of miR-21 by Ras in vivo and its role in tumor growth. D Frezzetti MD Menna P Zoppoli C Guerra A Ferraro AM Bello PD Luca C Calabrese A Fusco M Ceccarelli,, et al. Oncogene 30 275 286
45. miR-221 overexpression contributes to liver tumorigenesis. P Pineau S Volinia K McJunkin A Marchio C Battiston B Terris V Mazzaferro SW Lowe CM Croce A Dejean, Proc Natl Acad Sci U S A 2010 107 264 269 10.1073/pnas.0907904107 20018759
46. Extensive modulation of a set of microRNAs in primary glioblastoma. SA Ciafre S Galardi A Mangiola M Ferracin CG Liu G Sabatino M Negrini G Maira CM Croce MG Farace, Biochem Biophys Res Commun 2005 334 1351 1358 10.1016/j.bbrc.2005.07.030 16039986 (Pubitemid 41074723)
47. Functional links between clustered microRNAs: suppression of cell-cycle inhibitors by microRNA clusters in gastric cancer. YK Kim J Yu TS Han SY Park B Namkoong DH Kim K Hur MW Yoo HJ Lee HK Yang VN Kim, Nucleic Acids Res 2009 37 1672 1681 10.1093/nar/gkp002 19153141
48. MicroRNA cluster 221-222 and estrogen receptor alpha interactions in breast cancer. G Di Leva P Gasparini C Piovan A Ngankeu M Garofalo C Taccioli MV Iorio M Li S Volinia H Alder,, et al. J Natl Cancer Inst 2010 102 706 721 10.1093/jnci/djq102 20388878
49. FOXO3a: a novel player in thyroid carcinogenesis? S Karger C Weidinger K Krause SY Sheu T Aigner O Gimm KW Schmid H Dralle D Fuhrer, Endocr Relat Cancer 2009 16 189 199 18845647
50. Foxo3a regulates apoptosis by negatively targeting miR-21. K Wang PF Li, J Biol Chem 2010 285 16958 16966 10.1074/jbc.M109.093005 20371612
51. MiR-221 controls CDKN1C/p57 and CDKN1B/p27 expression in human hepatocellular carcinoma. F Fornari L Gramantieri M Ferracin A Veronese S Sabbioni GA Calin GL Grazi C Giovannini CM Croce L Bolondi M Negrini, Oncogene 2008 27 5651 5661 10.1038/onc.2008.178 18521080
52. Overexpressed cyclin D3 contributes to retaining the growth inhibitor p27 in the cytoplasm of thyroid tumor cells. G Baldassarre B Belletti P Bruni A Boccia F Trapasso F Pentimalli MV Barone G Chiappetta MT Vento S Spiezia,, et al. J Clin Invest 1999 104 865 874 10.1172/JCI6443 10510327 (Pubitemid 29536336)
53. Transformation of thyroid epithelium is associated with loss of c-kit receptor. PG Natali MT Berlingieri MR Nicotra A Fusco E Santoro A Bigotti G Vecchio, Cancer Res 1995 55 1787 1791 7536131
54. MicroRNA-dependent regulation of cKit in cutaneous melanoma. O Igoucheva V Alexeev, Biochem Biophys Res Commun 2009 379 790 794 10.1016/j.bbrc.2008.12. 152 19126397
55. miR-221&222 regulate TRAIL resistance and enhance tumorigenicity through PTEN and TIMP3 downregulation. M Garofalo G Di Leva G Romano G Nuovo SS Suh A Ngankeu C Taccioli F Pichiorri H Alder P Secchiero,, et al. Cancer Cell 2009 16 498 509 10.1016/j.ccr.2009.10.014 19962668
56. MicroRNA-221 and microRNA-222 regulate gastric carcinoma cell proliferation and radioresistance by targeting PTEN. Z Chun-Zhi H Lei Z An-Ling F Yan-Chao Y Xiao W Guang-Xiu J Zhi-Fan P Pei-Yu Z Qing-Yu K Chun-Sheng, BMC Cancer 2010 10 367 10.1186/1471-2407-10-367 20618998
57. Phosphoinositide 3-kinase signalling pathways in tumor progression, invasion and angiogenesis. S Brader SA Eccles, Tumori 2004 90 2 8 15143962 (Pubitemid 38541717)
58. Association of PTEN gene methylation with genetic alterations in the phosphatidylinositol 3-kinase/AKT signaling pathway in thyroid tumors. P Hou M Ji M Xing, Cancer 2008 113 2440 2447 10.1002/cncr.23869 18831514
59. Genetic alterations and their relationship in the phosphatidylinositol 3-kinase/Akt pathway in thyroid cancer. P Hou D Liu Y Shan S Hu K Studeman S Condouris Y Wang A Trink AK El-Naggar G Tallini,, et al. Clin Cancer Res 2007 13 1161 1170 10.1158/1078-0432.CCR-06-1125 17317825 (Pubitemid 46424056)
60. MicroRNA-21: from cancer to cardiovascular disease. V Jazbutyte T Thum, Curr Drug Targets 2010 11 926 935 10.2174/138945010791591403 20415649
61. OncomiRs: the discovery and progress of microRNAs in cancers. WC Cho, Mol Cancer 2007 6 60 10.1186/1476-4598-6-60 17894887
62. Involvement of human micro-RNA in growth and response to chemotherapy in human cholangiocarcinoma cell lines. F Meng R Henson M Lang H Wehbe S Maheshwari JT Mendell J Jiang TD Schmittgen T Patel, Gastroenterology 2006 130 2113 2129 10.1053/j.gastro.2006.02.057 16762633 (Pubitemid 43816961)
63. Programmed cell death 4 (PDCD4) is an important functional target of the microRNA miR-21 in breast cancer cells. LB Frankel NR Christoffersen A Jacobsen M Lindow A Krogh AH Lund, J Biol Chem 2008 283 1026 1033 17991735
64. MicroRNA-21 promotes cell transformation by targeting the programmed cell death 4 gene. Z Lu M Liu V Stribinskis CM Klinge KS Ramos NH Colburn Y Li, Oncogene 2008 27 4373 4379 10.1038/onc.2008.72 18372920 (Pubitemid 352010003)
65. MicroRNA-21 (miR-21) post-transcriptionally downregulates tumor suppressor Pdcd4 and stimulates invasion, intravasation and metastasis in colorectal cancer. IA Asangani SA Rasheed DA Nikolova JH Leupold NH Colburn S Post H Allgayer, Oncogene 2008 27 2128 2136 10.1038/sj.onc.1210856 17968323 (Pubitemid 351485639)
66. MicroRNA-21 targets tumor suppressor genes in invasion and metastasis. S Zhu H Wu F Wu D Nie S Sheng YY Mo, Cell Res 2008 18 350 359 10.1038/cr.2008.24 18270520 (Pubitemid 351333899)
67. MicroRNA 21 promotes glioma invasion by targeting matrix metalloproteinase regulators. G Gabriely T Wurdinger S Kesari CC Esau J Burchard PS Linsley AM Krichevsky, Mol Cell Biol 2008 28 5369 5380 10.1128/MCB.00479-08 18591254
68. Aberrant overexpression of microRNAs activate AKT signaling via down-regulation of tumor suppressors in natural killer-cell lymphoma/leukemia. Y Yamanaka H Tagawa N Takahashi A Watanabe YM Guo K Iwamoto J Yamashita H Saitoh Y Kameoka N Shimizu,, et al. Blood 2009 114 3265 3275 10.1182/blood-2009-06- 222794 19641183
69. Onco-miR-155 targets SHIP1 to promote TNFalpha-dependent growth of B cell lymphomas. IM Pedersen D Otero E Kao AV Miletic C Hother E Ralfkiaer RC Rickert K Gronbaek M David, EMBO Mol Med 2009 1 288 295 10.1002/emmm.200900028 19890474
70. MicroRNA-155 is regulated by the transforming growth factor beta/Smad pathway and contributes to epithelial cell plasticity by targeting RhoA. W Kong H Yang L He JJ Zhao D Coppola WS Dalton JQ Cheng, Mol Cell Biol 2008 28 6773 6784 10.1128/MCB.00941-08 18794355
71. MicroRNA-155 regulates cell survival, growth, and chemosensitivity by targeting FOXO3a in breast cancer. W Kong L He M Coppola J Guo NN Esposito D Coppola JQ Cheng, J Biol Chem 2010 285 17869 17879 10.1074/jbc.M110.101055 20371610
72. The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1. PA Gregory AG Bert EL Paterson SC Barry A Tsykin G Farshid MA Vadas Y Khew-Goodall GJ Goodall, Nat Cell Biol 2008 10 593 601 10.1038/ncb1722 18376396 (Pubitemid 351627379)
73. The miR-200 family determines the epithelial phenotype of cancer cells by targeting the E-cadherin repressors ZEB1 and ZEB2. SM Park AB Gaur E Lengyel ME Peter, Genes Dev 2008 22 894 907 10.1101/gad.1640608 18381893 (Pubitemid 351482843)
74. A reciprocal repression between ZEB1 and members of the miR-200 family promotes EMT and invasion in cancer cells. U Burk J Schubert U Wellner O Schmalhofer E Vincan S Spaderna T Brabletz, EMBO Rep 2008 9 582 589 10.1038/embor.2008.74 18483486 (Pubitemid 351772923)
75. The miR-200 family inhibits epithelial-mesenchymal transition and cancer cell migration by direct targeting of E-cadherin transcriptional repressors ZEB1 and ZEB2. M Korpal ES Lee G Hu Y Kang, J Biol Chem 2008 283 14910 14914 10.1074/jbc.C800074200 18411277
76. The ZEB/miR-200 feedback loop - a motor of cellular plasticity in development and cancer? S Brabletz T Brabletz, EMBO Rep 2010 11 670 677 10.1038/embor.2010.117 20706219
77. Anaplastic thyroid cancer: molecular pathogenesis and emerging therapies. RC Smallridge LA Marlow JA Copland, Endocr Relat Cancer 2009 16 17 44 18987168
78. Molecular profiling related to poor prognosis in thyroid carcinoma. Combining gene expression data and biological information. C Montero-Conde JM Martin-Campos E Lerma G Gimenez JL Martinez-Guitarte N Combalia D Montaner X Matias-Guiu J Dopazo A de Leiva,, et al. Oncogene 2008 27 1554 1561 10.1038/sj.onc.1210792 17873908 (Pubitemid 351347876)
79. The miR200 family of microRNAs regulates WAVE3-dependent cancer cell invasion. K Sossey-Alaoui K Bialkowska EF Plow, J Biol Chem 2009 284 33019 33029 10.1074/jbc.M109.034553 19801681
80. SMAD proteins control DROSHA-mediated microRNA maturation. BN Davis AC Hilyard G Lagna A Hata, Nature 2008 454 56 61 10.1038/nature07086 18548003 (Pubitemid 351931982)
81. Epithelial to mesenchymal transition is mechanistically linked with stem cell signatures in prostate cancer cells. D Kong S Banerjee A Ahmad Y Li Z Wang S Sethi FH Sarkar, PLoS One 2010 5 12445 10.1371/journal.pone.0012445 20805998
82. Induced pluripotent stem cell lines derived from human somatic cells. J Yu MA Vodyanik K Smuga-Otto J Antosiewicz-Bourget JL Frane S Tian J Nie GA Jonsdottir V Ruotti R Stewart,, et al. Science 2007 318 1917 1920 10.1126/science.1151526 18029452
83. Lin-28 interaction with the Let-7 precursor loop mediates regulated microRNA processing. MA Newman JM Thomson SM Hammond, RNA 2008 14 1539 1549 10.1261/rna.1155108 18566191
84. Selective blockade of microRNA processing by Lin28. SR Viswanathan GQ Daley RI Gregory, Science 2008 320 97 100 10.1126/science.1154040 18292307 (Pubitemid 351490762)
85. A feedback loop comprising lin-28 and let-7 controls pre-let-7 maturation during neural stem-cell commitment. A Rybak H Fuchs L Smirnova C Brandt EE Pohl R Nitsch FG Wulczyn, Nat Cell Biol 2008 10 987 993 10.1038/ncb1759 18604195
86. miR-200c regulates induction of apoptosis through CD95 by targeting FAP-1. R Schickel SM Park AE Murmann ME Peter, Mol Cell 2010 38 908 915 10.1016/j.molcel.2010.05.018 20620960
87. The 21-nucleotide let-7 RNA regulates developmental timing in Caenorhabditis elegans. BJ Reinhart FJ Slack M Basson AE Pasquinelli JC Bettinger AE Rougvie HR Horvitz G Ruvkun, Nature 2000 403 901 906 10.1038/35002607 10706289 (Pubitemid 30130993)
88. Conservation of the sequence and temporal expression of let-7 heterochronic regulatory RNA. AE Pasquinelli BJ Reinhart F Slack MQ Martindale MI Kuroda B Maller DC Hayward EE Ball B Degnan P Muller,, et al. Nature 2000 408 86 89 10.1038/35040556 11081512
89. The let-7 microRNA represses cell proliferation pathways in human cells. CD Johnson A Esquela-Kerscher G Stefani M Byrom K Kelnar D Ovcharenko M Wilson X Wang J Shelton J Shingara,, et al. Cancer Res 2007 67 7713 7722 10.1158/0008-5472.CAN-07-1083 17699775 (Pubitemid 47281364)
90. RAS is regulated by the let-7 microRNA family. SM Johnson H Grosshans J Shingara M Byrom R Jarvis A Cheng E Labourier KL Reinert D Brown FJ Slack, Cell 2005 120 635 647 10.1016/j.cell.2005.01.014 15766527 (Pubitemid 40343076)
91. MicroRNA let-7a down-regulates MYC and reverts MYC-induced growth in Burkitt lymphoma cells. VB Sampson NH Rong J Han Q Yang V Aris P Soteropoulos NJ Petrelli SP Dunn LJ Krueger, Cancer Res 2007 67 9762 9770 10.1158/0008-5472. CAN-07-2462 17942906 (Pubitemid 47621223)
92. The tumor suppressor microRNA let-7 represses the HMGA2 oncogene. YS Lee A Dutta, Genes Dev 2007 21 1025 1030 10.1101/gad.1540407 17437991 (Pubitemid 46686471)
93. Identification and characterization of lin-28 homolog B (LIN28B) in human hepatocellular carcinoma. Y Guo Y Chen H Ito A Watanabe X Ge T Kodama H Aburatani, Gene 2006 384 51 61 16971064 (Pubitemid 44755336)
94. Functional role for c-myc in mitogenic response to platelet-derived growth factor. HA Armelin MC Armelin K Kelly T Stewart P Leder BH Cochran CD Stiles, Nature 1984 310 655 660 10.1038/310655a0 6088986 (Pubitemid 14054330)
95. Immunohistochemical and sequencing analyses of the Wnt signaling components in Japanese anaplastic thyroid cancers. T Kurihara S Ikeda Y Ishizaki M Fujimori N Tokumoto Y Hirata S Ozaki M Okajima K Sugino T Asahara, Thyroid 2004 14 1020 1029 10.1089/thy.2004.14.1020 15650354 (Pubitemid 40076126)
96. Lin-28B transactivation is necessary for Myc-mediated let-7 repression and proliferation. TC Chang LR Zeitels HW Hwang RR Chivukula EA Wentzel M Dews J Jung P Gao CV Dang MA Beer,, et al. Proc Natl Acad Sci U S A 2009 106 3384 3389 10.1073/pnas.0808300106 19211792
97. Widespread microRNA repression by Myc contributes to tumorigenesis. TC Chang D Yu YS Lee EA Wentzel DE Arking KM West CV Dang A Thomas-Tikhonenko JT Mendell, Nat Genet 2008 40 43 50 10.1038/ng.2007.30 18066065
98. Transcriptional suppression of mir-29b-1/mir-29a promoter by c-Myc, hedgehog, and NF-kappaB. JL Mott S Kurita SC Cazanave SF Bronk NW Werneburg ME Fernandez-Zapico, J Cell Biochem 2010 110 1155 1164 10.1002/jcb.22630 20564213
99. Purification and properties of a protein that binds to the C-terminal coding region of human c-myc mRNA. RD Prokipcak DJ Herrick J Ross, J Biol Chem 1994 269 9261 9269 8132663 (Pubitemid 24209253)
100. VICKZ proteins: a multi-talented family of regulatory RNA-binding proteins. JK Yisraeli, Biol Cell 2005 97 87 96 15601260 (Pubitemid 40220715)
101. HMGA2 maintains oncogenic RAS-induced epithelial-mesenchymal transition in human pancreatic cancer cells. S Watanabe Y Ueda S Akaboshi Y Hino Y Sekita M Nakao, Am J Pathol 2009 174 854 868 10.2353/ajpath.2009.080523 19179606
102. HMGA2 and Smads co-regulate SNAIL1 expression during induction of epithelial-to-mesenchymal transition. S Thuault EJ Tan H Peinado A Cano CH Heldin A Moustakas, J Biol Chem 2008 283 33437 33446 10.1074/jbc.M802016200 18832382
103. Widespread changes in protein synthesis induced by microRNAs. M Selbach B Schwanhausser N Thierfelder Z Fang R Khanin N Rajewsky, Nature 2008 455 58 63 10.1038/nature07228 18668040
104. Adenovirus-mediated suppression of HMGI(Y) protein synthesis as potential therapy of human malignant neoplasias. S Scala G Portella M Fedele G Chiappetta A Fusco, Proc Natl Acad Sci U S A 2000 97 4256 4261 10.1073/pnas.070029997 10759549 (Pubitemid 30226120)
105. MicroRNA-mediated regulation of Ubc9 expression in cancer cells. F Wu S Zhu Y Ding WT Beck YY Mo, Clin Cancer Res 2009 15 1550 1557 10.1158/1078-0432. CCR-08-0820 19223510
106. Identification of novel microRNA targets based on microRNA signatures in bladder cancer. T Ichimi H Enokida Y Okuno R Kunimoto T Chiyomaru K Kawamoto K Kawahara K Toki K Kawakami K Nishiyama,, et al. Int J Cancer 2009 125 345- 352 10.1002/ijc.24390 19378336
107. Identification of microRNAs regulating reprogramming factor LIN28 in embryonic stem cells and cancer cells. X Zhong N Li S Liang Q Huang G Coukos L Zhang, J Biol Chem 2010
108. Silencing of microRNAs in vivo with 'antagomirs'. J Krutzfeldt N Rajewsky R Braich KG Rajeev T Tuschl M Manoharan M Stoffel, Nature 2005 438 685 689 10.1038/nature04303 16258535
109. Role for DNA methylation in the regulation of miR-200c and miR-141 expression in normal and cancer cells. L Vrba TJ Jensen JC Garbe RL Heimark AE Cress S Dickinson MR Stampfer BW Futscher, PLoS One 2010 5 8697 10.1371/journal.pone.0008697 20084174